Accueil
Nous joindre
Plan du site
Québec.ca
FAQ
English
Recherche avancée
Lois et règlements codifiés
Lois codifiées
Règlements codifiés
Lois et règlements annuels
Lois annuelles
Règlements annuels
Information complémentaire
L’Éditeur officiel du Québec
Quoi de neuf?
Note d’information
Politique du ministre de la Justice
Lois : Modifications
Lois : Dispositions non en vigueur
Lois : Entrées en vigueur
Lois annuelles : Versions PDF depuis 1996
Règlements : Modifications
Règlements annuels : Versions PDF depuis 1996
Décisions des tribunaux
a-6.001, r. 6.1
- Regulation respecting the fees payable to the Institut national d’excellence en santé et en services sociaux for the scientific evaluation of a drug, stable blood product or technology for listing purposes
Table des matières
Occurrences
0
Version courante
Texte complet
À jour au 19 juillet 2018
Ce document a valeur officielle.
chapter
A-6.001, r. 6.1
Regulation respecting the fees payable to the Institut national d’excellence en santé et en services sociaux for the scientific evaluation of a drug or a stable blood product
FINANCIAL ADMINISTRATION — FEES PAYABLE — STABLE BLOOD PRODUCT
Financial Administration Act
(chapter A-6.001, s. 83.8)
.
A-6.001
06
June
20
2018
07
July
19
2018
1
.
A manufacturer who asks the Institut national d’excellence en santé et en services sociaux to conduct a scientific evaluation of a drug or a stable blood product shall pay the fees set out in Schedule 1.
These fees vary according to the scientific evaluation that the Institut decides to conduct after receiving the request from the manufacturer.
861-2018
O.C. 861-2018
,
s.
1
.
2
.
As used in this regulation:
“
scientific evaluation
”
: means a structured evaluation, the objective of which is to guide decision-making, of a health technology that can concern both the direct impact of that technology and its indirect and unintentional consequences;
“
manufacturer
”
: means a person or group of persons who manufacture, produce, import or sell, under their name or a brand name, drugs or stable blood products;
“
indication
”
: means the indication for use requested by a manufacturer;
“
drug
”
: means a product that can be entered on the list of medications referred to in section 60 of An Act respecting prescription drug insurance (
chapter A-29.01
) or on the lists of medications referred to in section 116 of An Act respecting health services and social services (
chapter S-4.2
) or in section 150 of An Act respecting health services and social services for Cree Native persons (
chapter S-5
);
“
stable blood product
”
: means an acellular component of blood with the storage characteristics of drugs and that is used to treat certain disorders due to an imbalance in the circulatory system or certain specific diseases.
861-2018
O.C. 861-2018
,
s.
2
.
3
.
The fees stipulated in this regulation are non-refundable.
861-2018
O.C. 861-2018
,
s.
3
.
4
.
The fees stipulated in this regulation are indexed in the manner set out in chapter VIII.1 of the Financial Administration Act (
chapter A-6.001
).
The Minister of Health and Social Services shall publish the result of the indexation in Part 1 of the
Gazette officielle du Québec
.
861-2018
O.C. 861-2018
,
s.
4
.
5
.
(Omitted).
861-2018
O.C. 861-2018
,
s.
5
.
SCHEDULE I
(
s. 1
)
FEES PAYABLE FOR THE DIFFERENT SCIENTIFIC EVALUATIONS
Scientific Evaluation
Fee
Health technology evaluated
Type of evaluation
New drug or new indication for a currently listed drug
First evaluation
$38,921 per indication
Reevaluation
$19,460 per indication
Biosimilar
First evaluation
$7,784 per submission
Subsequent evaluation
(i.e., addition of an indication)
$7,784 per submission
Reevaluation
$3,892 per submission
Subsequent entry non-biological complex drug
First evaluation
$7,784 per submission
Subsequent evaluation
(i.e., addition of an indication)
$7,784 per submission
Reevaluation
$3,892 per submission
New strength(s) or new form(s) of a currently listed drug
First evaluation
$3,892 per submission
Reevaluation
$1,946 per submission
New nutritional formula, new dressing or new combination of currently listed drugs
First evaluation
$5,189 per submission
Reevaluation
$2,595 per submission
Diagnostic agent of a currently listed non-proprietary name
First evaluation
$2,595 per submission
Reevaluation
$1,297 per submission
Exemption from the application of the lowest price
Any exemption request
$6,487 per submission
New stable blood product
First evaluation
$32,744 per submission
Reevaluation
$16,372 per submission
861-2018
O.C. 861-2018
,
Sch. I
.
REFERENCES
O.C. 861-2018, 2018 G.O. 2, 2774
Copier
Sélectionner cet élément
Sélectionner l'élément parent
Désélectionner tous les éléments
Copier vers Rédaction
Copier vers LAW
Copier vers le presse-papier
×
Pour copier : Ctrl+C
0
Nous joindre
Plan du site
Québec.ca
Accessibilité
Politique de confidentialité
© Gouvernement du Québec
Sélections
×
Afficher
Les sélections du document courant
Toutes les sélections de la collection
Fragments sélectionnés
Supprimer toutes les sélections
Afficher les sélections
Cyberlex
×
Version 2.2.0.3